Search Result

Results for "

editing

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Deaminase (2) Adrenergic Receptor (1) Apoptosis (1) Bacterial (2) Biochemical Assay Reagents (5) DNA/RNA Synthesis (5) FGFR (1) Fluorescent Dye (2) IFNAR (1) Liposome (9) mRNA (1) Necroptosis (1) Nucleoside Antimetabolite/Analog (2) Phosphoramidites (1) VEGFR (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (4)
Oligonucleotides:	Hypoxanthine (1) mRNA (1) Cationic Lipids (7) Antisense Oligonucleotides (4) Phosphoramidites (1) Gene Editing (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

MCE Kits

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150279

PolQi2 3 Publications Verification	DNA/RNA Synthesis	Others
PolQi2 is a PolΘ inhibitor that targets and inhibits alt-EJ (alternative end-joining) repair by inhibiting the helicase domain at the N-terminus of PolΘ. PolQi2 enhances the precision and integration efficiency of gene editing at different loci and in various cell lines. Furthermore, the combined use of PolQi2 with DNA-PK inhibitors reduces the off-target effects of Cas9. PolQi2 can be used in gene editing research .

HY-115686

8-Azaadenosine 5 Publications Verification	Adenosine Deaminase	Inflammation/Immunology Cancer
8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells .

HY-19334

L755507 2 Publications Verification	Adrenergic Receptor	Endocrinology Cancer
L755507 is a potent, selective agonist of β₃-AR with an IC₅₀ of 35 nM. L755507 enhances the homology-directed repair (HDR)-mediated genome editing .

HY-145442

8-Azanebularine	Adenosine Deaminase	Others
8-Azanebularine, a compound with hydrogen in place of the C6 amino group, inhibits the ADAR2 reaction at high concentrations (IC₅₀=15 mM). 8-Azanebularine is incorporated into an RNA structure recognized by human ADAR2 results in high-affinity binding (K_D=2 nM). 8-Azanebularine can be used for the research of ADAR-catalyzed RNA-editing reaction .

HY-P5307

Peptide A5K INF7-A5K-TAT	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-159078

PolQi1	DNA/RNA Synthesis	Cancer
PolQi1 is a selective inhibitor targeting the Polθ domain of DNA polymerase. PolQi1 inhibits the Polθ-mediated microhomology end joining (TMEJ/alt-EJ) pathway, reducing insertion/deletion (Indels) and imprecise editing events during DNA repair. PolQi1 can enhance the efficiency and accuracy of homology-directed repair (HDR) or Prime editing, and reduce off-target effects; and in combination with DNA-PK inhibitor AZD-7648 (HY-111783), exert efficient genome editing capabilities with dual pathway regulation. PolQi1 can be mainly used in gene editing research (such as CRISPR-Cas9 or Prime editing system optimization) to improve the precision editing efficiency of difficult-to-edit cells (such as primary hepatocytes and mouse embryos) .

HY-145795

OF-02	Liposome	Others
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

HY-150229

306-N16B	Liposome	Cancer
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

HY-139306

BAMEA-O16B	Liposome	Inflammation/Immunology
BAMEAO16B is a lipid nanoparticle. BAMEAO16B integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing. BAMEAO16B can be used for the research of gene editing .

HY-136251

BRD0539	Bacterial	Infection
BRD0539 is a Streptococcus pyogenes Cas9 (SpCas9) inhibitor with an IC₅₀ of 22 μM in an in vitro DNA cleavage assay .

HY-156257

UNC9512 1 Publications Verification	DNA/RNA Synthesis	Cancer
UNC9512 is a selective 53BP1 inhibitor with an IC₅₀ of 0.46 μM, and a K_d values of 0.17 μM. UNC9512 binds 53BP1 and its tandem Tudor domain, disrupts histone H4 interaction, and inhibits 53BP1 activity. UNC9512 can be used as a probe for DNA damage repair and Gene editing .

HY-W010744

DMT-dI 5'-O-DMT-dI; 2'-Deoxy-5'-O-DMT-inosine	Phosphoramidites Nucleoside Antimetabolite/Analog	Cancer
DMT-dI (5'-O-DMT-dI) is a deoxyribonucleoside containing a hypoxanthine base. DMT-dI can be used to prepare convertible nucleoside derivatives to prepare modified oligonucleotides complementary to target genes for gene editing. DMT-dI can be used to study various conditions, disorders or diseases modified by adenosine .

HY-147412

Ultevursen QR-421a	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis	Neurological Disease
Ultevursen (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .

HY-172526

4A3-SCC-10	Liposome	Cancer
4A3-SCC-10 is a biodegradable ionizable lipid containing disulfide bonds. 4A3-SCC-10 can be used to prepare lipid nanoparticles (LNPs) for the delivery of mRNA in vitro and in vivo. 4A3-SCC-10 can be used for broad applications such as gene editing, vaccine, and cancer detection .

HY-E70220

AsCas12a Nuclease	Biochemical Assay Reagents	Others
AsCas12a Nuclease is a nuclease, and can specifically cutting double-stranded DNA. AsCas12a Nuclease can be used for gene edited study .

HY-159709

VL-422	Liposome	Metabolic Disease
VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .

HY-176754

TCL065	Liposome	Metabolic Disease Inflammation/Immunology
TCL065 is an ionizable lipid with a pK_a of 6.3. TCL065 can be used to generate lipid nanoparticles (LNPs) for the delivery of mRNA as well as single-guide RNA (sgRNA) both in vitro and in vivo. TCL065-containing LNPs can studied in research for Duchenne muscular dystrophy and gene-editing technologies .

HY-P5307A

Peptide A5K acetate INF7-A5K-TAT acetate	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-174499

Cas9 Nickase D10A mRNA (5moU)	mRNA	Others
Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.

HY-153138

FTT5 LLNs	Biochemical Assay Reagents	Others
FTT5 LLNs are functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing .

HY-171953

THP1 Lipid	Liposome	Others
THP1 Lipid is an ionizable lipidoid. THP1 Lipid can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to muscles with minimal toxicity and editing genes in specific liver tissues in tdTomato transgenic mice model. THP1 Lipid can be used for vaccine delivery and CRISPR/Cas9-mediated gene editing research .

HY-165604

C14-490	Liposome	Others
C14-490, an ionizable cationic lipid (pKa = 5.94), is used for the synthesis of lipid nanoparticles (LNPs). C14-490 LNPs is used as the basis for subsequent study of in utero gene editing in HSCs. C14-490 LNPs are used to encapsulate SpCas9 mRNA and TTR sgRNA using optimized B5 formulation parameters and surface conjugation to CD45 antibody F(ab’)₂ fragments-Systematically optimized Targeted Editing Machinery LNPs (STEM LNPs) .

HY-145692

Cas9-IN-3	Bacterial	Others
Cas9-IN-3 is a potent Cas9 inhibitor (IC₅₀=28 μM) .

HY-165603

Si5-N14	Liposome VEGFR FGFR	Cardiovascular Disease Inflammation/Immunology Cancer
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .

HY-P11639

ppTG21	Biochemical Assay Reagents	Others
ppTG21 is an endosomolytic agent and inducer. ppTG21 can facilitate endosomal escape of Cas9-2lig-1NLS and Cas9-ASGPrL ribonucleoproteins (RNPs) to enable receptor-facilitated, cell-type specific gene editing in cancer cells without electroporation or transfection reagents. ppTG21 can be used for the research of gene editing .

HY-181129

ADAR1i-124	DNA/RNA Synthesis IFNAR Apoptosis Necroptosis	Cancer
ADAR1i-124 is an A-to-I RNA editing inhibitor by inhibiting the catalytic activities of both ADAR1p150 and ADAR1p110. ADAR1i-124 activates type I interferon (IFN) and ZBP1 pathways and dose-dependently inhibits viability across different types of cancer cell lines. ADAR1i-124 can induce cells apoptosis and necroptosis. ADAR1i-124 can be used for the research of cancer, such as cutaneous melanoma and ovarian cancer .

HY-185504

Nexiguran	Others	Others
Nexiguran is one component of Nexiguran ziclumeran and also an sgRNA targeting the human TTR gene. Nexiguran ziclumeran (NTLA-2001) is a CRISPR gene-editing therapy that targets hepatic TTR, and it can also be used for research on transthyretin amyloidosis .

HY-147412D

FAM labled Ultevursen sodium	Fluorescent Dye	Neurological Disease
FAM labled Ultevursen sodiumis a FAM labled Ultevursen sodium (HY-147412A). Ultevursen sodium (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen sodium binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen sodium exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen sodium can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .

HY-147412E

Cy3 labled Ultevursen sodium	Fluorescent Dye	Neurological Disease
Cy3 labled Ultevursen sodium is a Cy3 labled Ultevursen sodium (HY-147412A). Ultevursen sodium (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen sodium binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen sodium exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen sodium can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .

Cat. No.	Product Name

HY-L244

*High-Efficiency Gene Editing* Compound Library**	724 compounds
In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies. To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 724 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

High-Efficiency Gene Editing Compound Library

724 compounds

In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies.

To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 724 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

HY-L251

Ionizable Lipid Compound Library	0 compounds
Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application. To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 0 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.

Ionizable Lipid Compound Library

0 compounds

Ionizable lipids are a class of specialized, functional lipid molecules with pH-sensitive charge characteristics. They are primarily divided into two major categories: ionizable cationic lipids and ionizable anionic lipids, though the term typically specifies ionizable cationic lipids within the biomedical field. Structurally, these lipids consist of an ionizable hydrophilic headgroup, a biodegradable linker, and hydrophobic tails. Their primary application is serving as the key delivery vehicle in lipid nanoparticles (LNPs) to encapsulate negatively charged nucleic acid macromolecules, such as mRNA vaccines, siRNA therapeutics, and CRISPR gene-editing components. In a physiological, neutral environment, they remain electrically neutral to minimize systemic toxicity and prolong circulation time. Upon entering the acidic microenvironment of cellular endosomes, however, they undergo protonation to become positively charged, thereby inducing membrane fusion and enabling the highly efficient intracellular release of the nucleic acid cargo. Consequently, they serve as the technological cornerstone for bringing nucleic acid therapies into clinical application.

To accelerate the translational process of cutting-edge nucleic acid drugs, MCE has meticulously constructed an ionizable lipid compound library containing 0 high-performance molecules, aiming to provide researchers and pharmaceutical professionals with a high-throughput, multi-dimensional lipid screening platform.

Cat. No.	Product Name	Type

HY-145795

OF-02	Biochemical Assay Reagents
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

OF-02

Biochemical Assay Reagents

OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

HY-150229

306-N16B	Biochemical Assay Reagents
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

306-N16B

Biochemical Assay Reagents

306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

HY-139306

BAMEA-O16B	Biochemical Assay Reagents
BAMEAO16B is a lipid nanoparticle. BAMEAO16B integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing. BAMEAO16B can be used for the research of gene editing .

Cat. No.	Product Name	Target	Research Area

HY-P5307

Peptide A5K INF7-A5K-TAT	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-P10999

INF7TAT-P55 P55	Peptides	Others
INF7TAT-P55 (P55) is a peptide that enables ribonucleoprotein delivery for CRISPR engineering. INF7TAT-P55 supports efficient genome editing in T cells with excellent yields, and is well suited for CD34+ HSPCs .

HY-P5307A

Peptide A5K acetate INF7-A5K-TAT acetate	Biochemical Assay Reagents	Others
Peptide A5K (INF7-A5K-TAT) acetate is an amphiphilic peptide derived from the HA2-TAT fusion scaffold. Peptide A5K acetate can non-covalently bind to CRISPR ribonucleoproteins and efficiently deliver them to cells, such as primary human T cells, B cells, and NK cells. Peptide A5K acetate enables low-toxicity, precise, and multiplex genome editing, holding great application potential in the field of cell therapy .

HY-P11639

ppTG21	Biochemical Assay Reagents	Others
ppTG21 is an endosomolytic agent and inducer. ppTG21 can facilitate endosomal escape of Cas9-2lig-1NLS and Cas9-ASGPrL ribonucleoproteins (RNPs) to enable receptor-facilitated, cell-type specific gene editing in cancer cells without electroporation or transfection reagents. ppTG21 can be used for the research of gene editing .

Cat. No.	Product Name

HY-KE7066

FnCas12a
FnCas12a(Cpf1), is an RNA-guided, DNA-editable recombinant endonuclease that can be used for gene editing and detection.

HY-K2028

*OptiLNP Gene Editing* Kit (Immune Cells)**
MCE OptiLNP Gene Editing Kit (Immune Cells) is a ready-to-use transfection reagent based on LNP technology. It is designed for the efficient co-transfection of Cas9 mRNA and sgRNA during gene editing inimmune cells.

HY-K2027

*OptiLNP Gene Editing* Kit**
MCE OptiLNP Gene Editing Kit is a ready-to-use transfection reagent based on LNP technology. It is designed for the efficient co-transfection of Cas9 mRNA and sgRNA during gene editing in common cells (adherent or suspension cells).

Species:	Human (2)
Tag:	SUMO (1) His (2)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P72080

	APOBEC3A Protein, Human (His-SUMO) A3A; ABC3A_HUMAN; APOBEC3A; Apolipoprotein B mRNA editing enzyme; Apolipoprotein B mRNA editing enzyme; catalytic polypeptide like 3A; ARP3; bK150C2.1; Catalytic polypeptide like 3A; Phorbolin 1; Phorbolin-1; PHRBN; Probable DNA dC >dU editing enzyme APOBEC-3A; Probable DNA dC->dU-editing enzyme APOBEC-3A	Human	E. coli
	APOBEC3A protein is a DNA deaminase that limits the mobility of viruses, foreign DNA, and retrotransposons. APOBEC3A Protein, Human (His-SUMO) is the recombinant human-derived APOBEC3A protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.

HY-P76131

	AARSD1 Protein, Human (His) Alanyl-tRNA editing protein Aarsd1; Alanyl-tRNA synthetase domain-containing protein 1; AARSD1	Human	E. coli
	AARSD1 Protein actively functions in trans to edit the amino acid moiety from incorrectly charged tRNA(Ala). AARSD1 Protein, Human (His) is the recombinant human-derived AARSD1 protein, expressed by E. coli , with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-145795

OF-02		Cationic Lipids
OF-02 is an ionizable lipid for mRNA delivery and a key component of lipid nanoparticles (LNPs). OF-02 is protonated in the acidic endosomal environment to promote endosomal escape of mRNA and efficiently induce protein expression in target cells. OF-02 relies on the pH-responsive membrane fusion properties to form a complex with mRNA and destroy the endosomal membrane structure to achieve mRNA release in the cytoplasm. OF-02 is mainly used in the development of mRNA vaccines, gene editing, and protein replacement therapy[1][2][3].

HY-150229

306-N16B		Cationic Lipids
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .

HY-139306

BAMEA-O16B		Cationic Lipids
BAMEAO16B is a lipid nanoparticle. BAMEAO16B integrated with disulfide bonds, can efficiently deliver Cas9 mRNA and sgRNA into cells while releasing RNA in response to the reductive intracellular environment for genome editing. BAMEAO16B can be used for the research of gene editing .

HY-W010744

DMT-dI 5'-O-DMT-dI; 2'-Deoxy-5'-O-DMT-inosine		Phosphoramidites Hypoxanthine
DMT-dI (5'-O-DMT-dI) is a deoxyribonucleoside containing a hypoxanthine base. DMT-dI can be used to prepare convertible nucleoside derivatives to prepare modified oligonucleotides complementary to target genes for gene editing. DMT-dI can be used to study various conditions, disorders or diseases modified by adenosine .

HY-147412

Ultevursen QR-421a		Antisense Oligonucleotides
Ultevursen (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .

HY-159709

VL-422		Cationic Lipids
VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .

HY-147412A

Ultevursen sodium QR-421a sodium		Antisense Oligonucleotides
Ultevursen sodium (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen sodium binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen sodium exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen sodium can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .

HY-176754

TCL065		Cationic Lipids
TCL065 is an ionizable lipid with a pK_a of 6.3. TCL065 can be used to generate lipid nanoparticles (LNPs) for the delivery of mRNA as well as single-guide RNA (sgRNA) both in vitro and in vivo. TCL065-containing LNPs can studied in research for Duchenne muscular dystrophy and gene-editing technologies .

HY-174499

Cas9 Nickase D10A mRNA (5moU)		mRNA Gene Editing
Cas9 Nickase D10A mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9) that contains a D10A amino acid substitution. This mRNA also contains a C-terminal nuclear localization signal followed by a HA tag.Cas9 functions as part of the CRISPR (clustered regularly interspaced short palindromic repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform the DNA cleavage. While wild-type Cas9 creates a double-stranded break at the target site, Cas9 nickase creates a single-stranded break. This favors homology-directed repair and decreases the occurrence of non-homologous end joining.

HY-153138

FTT5 LLNs		Cationic Lipids
FTT5 LLNs are functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing .

HY-171953

THP1 Lipid		Cationic Lipids
THP1 Lipid is an ionizable lipidoid. THP1 Lipid can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to muscles with minimal toxicity and editing genes in specific liver tissues in tdTomato transgenic mice model. THP1 Lipid can be used for vaccine delivery and CRISPR/Cas9-mediated gene editing research .

HY-147412D

FAM labled Ultevursen sodium		Antisense Oligonucleotides
FAM labled Ultevursen sodiumis a FAM labled Ultevursen sodium (HY-147412A). Ultevursen sodium (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen sodium binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen sodium exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen sodium can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .

HY-147412E

Cy3 labled Ultevursen sodium		Antisense Oligonucleotides
Cy3 labled Ultevursen sodium is a Cy3 labled Ultevursen sodium (HY-147412A). Ultevursen sodium (QR-421a) is a splice-modulating antisense oligonucleotide targeting exon 13 of the USH2A gene, which restores the functional expression of Usherin protein by inducing exon skipping. Ultevursen sodium binds to USH2A pre-mRNA and modulates the splicing process to specifically skip exon 13 carrying the pathogenic mutation c.2299delG, generating an in-frame transcript and a truncated yet functionally normal protein. Ultevursen sodium exhibits concentration-dependent exon skipping activity in human cells and retinal organoid models, and restores Usherin expression and retinal function in zebrafish and gene-edited mouse models. Ultevursen sodium can be used for related research on type 2 Usher syndrome and non-syndromic retinitis pigmentosa .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: